Back to Agenda
FDA Science Strategies: Purposeful Scientific Leadership to Advance Innovation and Improve Patient Outcomes
Session Chair(s)
Meghana Chalasani, MHA
Associate Director for Clinical Trial Innovation, Office of New Drugs, CDER, FDA, United States
This forum will provide an overview of FDA CDER’s Science Strategies Program. It will also provide an opportunity for stakeholders, including patients and drug developers, to share their experiences, perspectives and priorities to inform FDA’s efforts.
Learning Objective : Describe FDA Center for Drug Evaluation and Research’s Office of New Drugs' efforts to enhance therapeutic-specific strategic planning and scientific leadership; Discuss the opportunities for key stakeholders including, patients, academia, drug developers, health care providers, and payers, to help advance FDA’s therapeutic-specific science strategies.
Speaker(s)
Klaus Romero, MD, MS
Chief Executive Officer (CEO), Critical Path Institute, United States
Panelist
Jeffrey Nahum Siegel, DrMed, MD
Director, Office of Drug Evaluation Sciences, OND, CDER, FDA, United States
Panelist
Michelle Campbell, PHD
Associate Director, Stakeholder Engagement and Clinical Outcomes, ON, OND, CDER, FDA, United States
Panelist
Meaghan Malley
Senior Project Associate, Kidney Health Initiative, ASN Alliance for Kidney Health, United States
Panelist
Have an account?